HTML Microdata document

This HTML5 document contains 68 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

Prefix	IRI
n2	http://linked.opendata.cz/resource/drugbank/drug/
dcterms	http://purl.org/dc/terms/
n26	http://linked.opendata.cz/resource/drugbank/drug/DB00637/identifier/pubchem-substance/
n13	http://linked.opendata.cz/resource/drugbank/drug/DB00637/identifier/kegg-drug/
n22	http://linked.opendata.cz/resource/drugbank/drug/DB00637/identifier/drugbank/
n15	http://linked.opendata.cz/resource/drugbank/drug/DB00637/identifier/iuphar/
foaf	http://xmlns.com/foaf/0.1/
n19	http://linked.opendata.cz/resource/drugbank/drug/DB00637/identifier/guide-to-pharmacology/
n24	http://bio2rdf.org/drugbank:
n20	http://linked.opendata.cz/resource/drugbank/drug/DB00637/identifier/chemspider/
adms	http://www.w3.org/ns/adms#
n21	http://www.drugs.com/mtm/
n10	http://www.rxlist.com/cgi/generic/
n8	http://linked.opendata.cz/resource/drugbank/drug/DB00637/identifier/chebi/
n12	http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdf	http://www.w3.org/1999/02/22-rdf-syntax-ns#
owl	http://www.w3.org/2002/07/owl#
n3	http://linked.opendata.cz/ontology/drugbank/
n14	http://linked.opendata.cz/resource/drugbank/drug/DB00637/identifier/pharmgkb/
n6	http://linked.opendata.cz/resource/drugbank/drug/DB00637/identifier/wikipedia/
n4	http://linked.opendata.cz/resource/drugbank/property/
xsdh	http://www.w3.org/2001/XMLSchema#
n16	http://linked.opendata.cz/resource/drugbank/drug/DB00637/identifier/kegg-compound/
n7	http://linked.opendata.cz/resource/drugbank/drug/DB00637/identifier/bindingdb/
n25	http://linked.opendata.cz/resource/drugbank/drug/DB00637/identifier/pubchem-compound/
n18	http://linked.opendata.cz/resource/atc/
n17	http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item: n2:DB00637
rdf:type: n3:Drug
n3:description: Astemizole is a long-acting, non-sedating second generation antihistamine used in the treatment of allergy symptoms. It was withdrawn from market by the manufacturer in 1999 due to the potential to cause arrhythmias at high doses, especially when when taken with CYP inhibitors or grapefruit juice.
n3:generalReferences: # Wang X, Hockerman GH, Green HW 3rd, Babbs CF, Mohammad SI, Gerrard D, Latour MA, London B, Hannon KM, Pond AL: Merg1a K+ channel induces skeletal muscle atrophy by activating the ubiquitin proteasome pathway. FASEB J. 2006 Jul;20(9):1531-3. Epub 2006 May 24. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/16723379 # Chong CR, Chen X, Shi L, Liu JO, Sullivan DJ Jr: A clinical drug library screen identifies astemizole as an antimalarial agent. Nat Chem Biol. 2006 Aug;2(8):415-6. Epub 2006 Jul 2. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/16816845
n3:group: withdrawn approved
n3:halfLife: 1 day
n3:indication: Astemizole was indicated for use in the relieving allergy symptoms, particularly rhinitis and conjunctivitis. It has been withdrawn from the market however due to concerns of arrhythmias.
owl:sameAs: n12:DB00637 n24:DB00637
dcterms:title: Astemizole
adms:identifier: n6:Astemizole n7:24226 n8:2896 n13:D00234 n14:PA448498 n15:2603 n16:C06832 n19:2603 n20:2160 n22:DB00637 n25:2247 n26:46508569
n3:mechanismOfAction: Astemizole competes with histamine for binding at H1-receptor sites in the GI tract, uterus, large blood vessels, and bronchial muscle. This reversible binding of astemizole to H1-receptors suppresses the formation of edema, flare, and pruritus resulting from histaminic activity. As the drug does not readily cross the blood-brain barrier and preferentially binds at H1 receptors in the peripehery rather than within the brain, CNS depression is minimal. Astemizole may also act on H3-receptors, producing adverse effects.
n3:synonym: Astemizol 1-(P-Fluorobenzyl)-2-((1-(2-(P-methoxyphenyl)ethyl)piperid-4-yl)amino)benzimidazole Astemizolum Astemison 1-(P-Fluorobenzyl)-2-((1-(P-methoxyphenethyl)-4-piperidyl)amino)benzimidazole Astémizole
n3:toxicity: LD50=2052mg/kg in mice
n3:foodInteraction: Take on an empty stomach, food decreases absorption by 60%.
n3:proteinBinding: 96.7%
n3:synthesisReference: Godelieve Irma Christine Maria Heylen, Cornelus Gerardus Maria Janssen, Jurzak Mirek, Henricus Petrus Martinus Maria Van Assouw, "Radiolabeled astemizole and method of making." U.S. Patent US07541476, issued June 02, 2009.
foaf:page: n10:astem.htm n21:astemizole.html
n3:IUPAC-Name: n4:271B5DD5-363D-11E5-9242-09173F13E4C5
n3:InChI: n4:271B5DDB-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula: n4:271B5DDA-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight: n4:271B5DD7-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight: n4:271B5DD8-363D-11E5-9242-09173F13E4C5
n3:SMILES: n4:271B5DD9-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility: n4:271B5DD3-363D-11E5-9242-09173F13E4C5 n4:271B5DEA-363D-11E5-9242-09173F13E4C5
n3:logP: n4:271B5DD4-363D-11E5-9242-09173F13E4C5 n4:271B5DD1-363D-11E5-9242-09173F13E4C5 n4:271B5DEC-363D-11E5-9242-09173F13E4C5
n3:logS: n4:271B5DD2-363D-11E5-9242-09173F13E4C5
n17:hasATCCode: n18:R06AX11
n3:H-Bond-Acceptor-Count: n4:271B5DE1-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count: n4:271B5DE2-363D-11E5-9242-09173F13E4C5
n3:InChIKey: n4:271B5DDC-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-: n4:271B5DDD-363D-11E5-9242-09173F13E4C5
n3:Polarizability: n4:271B5DDF-363D-11E5-9242-09173F13E4C5
n3:Refractivity: n4:271B5DDE-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count: n4:271B5DE0-363D-11E5-9242-09173F13E4C5
n3:absorption: Rapidly absorbed from the gastrointestinal tract.
n3:affectedOrganism: Humans and other mammals
n3:casRegistryNumber: 68844-77-9
n3:category
n3:Bioavailability: n4:271B5DE6-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter: n4:271B5DE8-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule: n4:271B5DE9-363D-11E5-9242-09173F13E4C5
n3:Melting-Point: n4:271B5DEB-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings: n4:271B5DE5-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge: n4:271B5DE4-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five: n4:271B5DE7-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name: n4:271B5DD6-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-: n4:271B5DE3-363D-11E5-9242-09173F13E4C5